Prostate cancer – Therapy with radium-223

Prostate cancer – Therapy with radium-223

Bibliographic Details
Main Authors:	Ana Emília Brito, Bárbara Juarez Amorim, Milena Martello, Wanderley Marques Bernardo, Elba Etchebehere
Format:	Article
Language:	English
Published:	Associação Médica Brasileira
Series:	Revista da Associação Médica Brasileira
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017001201019&lng=en&tlng=en

Similar Items

Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
by: Elba Etchebehere, et al.

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Radium-223 for the treatment of castration-resistant prostate cancer
by: El-Amm J, et al.
Published: (2015-05-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases
by: V. B. Matveev, et al.
Published: (2017-10-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01)

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
by: A. D. Kaprin, et al.
Published: (2018-07-01)

Radium 223 in metastatic castration resistant prostate prostate. Effectiveness in clinical practice
by: M.C. Salas Buzón, et al.
Published: (2020-11-01)

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice
by: Raniv D. Rojo, et al.
Published: (2021-01-01)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
by: Andrew J Armstrong, et al.
Published: (2019-01-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
by: Stefano Casarin, et al.
Published: (2020-06-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations
by: T Yu. Kochetova, et al.
Published: (2020-04-01)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
by: Anil Kapoor, et al.
Published: (2020-01-01)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Rodolfo Borges dos Reis, et al.

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
by: Mukherji D, et al.
Published: (2014-05-01)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
by: Roviello G, et al.
Published: (2018-12-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases
by: М. I. Volkova, et al.
Published: (2019-07-01)

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
by: Kalevi Kairemo, et al.
Published: (2015-07-01)

Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice
by: K. M. Nyushko, et al.
Published: (2020-01-01)

Efficacy and safety of radium-223 in routine clinical practice
by: V. B. Matveev, et al.
Published: (2021-02-01)

Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait
by: V. N. Oschepkov, et al.
Published: (2019-01-01)

Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases
by: Christina Hague, et al.
Published: (2016-06-01)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
by: Renzulli II JF, et al.
Published: (2015-06-01)

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
by: Jeroen H. A. Creemers, et al.
Published: (2021-05-01)

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-01-01)

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
by: Stephanie I Kim, et al.
Published: (2021-01-01)

Fatal Pancytopenia Associated with Radium-223 Dichloride in a Patient with Castration-Resistant Prostate Cancer and Multiple Bone Metastases
by: Yukihiro Hama, et al.
Published: (2018-02-01)

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
by: Harrison MR, et al.
Published: (2013-01-01)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
by: Theodoros G. Soldatos, et al.
Published: (2019-05-01)

Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience
by: Renato P. Costa, et al.
Published: (2019-03-01)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01)

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223
by: Esmail M. Al‐Ezzi, et al.
Published: (2021-09-01)

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
by: Kaoru Maruyama, et al.
Published: (2018-01-01)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
by: Masato Dobashi, et al.
Published: (2020-09-01)